Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer

Table 1 Comparison of general data between the two groups

General information	Control group (n = 43)	Observation group (n = 39)	t/χ2	P value
Gender (n)			0.413	0.521
Male	24	19
Female	19	20
Age (yr), mean ± SD	46.02 ± 7.28	48.37 ± 6.41	1.545	0.126
BMI (kg/m2), mean ± SD	22.45 ± 3.46	23.01 ± 2.98	0.781	0.437
Histological classification (n)			0.427	0.808
Adenocarcinoma	27	22
Mucinous cancer	12	12
Undifferentiated carcinoma	4	5
TNM stage (n)			2.201	0.138
III	12	17
IV	31	22

BMI: Body mass index; TNM: Tumor-node-metastasis.